CURE Pharmaceutical Announces Completion of FDA Pre-IND Review and Clinical Trial Plans for CUREfilm Blue™ for Erectile Dysfunction

GlobeNewswire• March 26, 2019 OXNARD, Calif., March 26, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has successfully completed a pre-IND (Investigational New Drug) review with the U.S. Food and Drug Administration (FDA). The FDA provided feedback supportive of CURE’s clinical development plans for its CUREfilm…

Wealth Announces Option For 100% Of Meductic Vanadium Property

GlobeNewswire •March 13, 2019 Cancels Incentive Stock Options VANCOUVER, British Columbia, March 13, 2019 (GLOBE NEWSWIRE) — Wealth Minerals Ltd. (the “Company” or “Wealth”) – (TSXV: WML; OTCQX: WMLLF; SSE: WMLCL; Frankfurt: EJZN), announces that it has signed an option agreement giving it the right (the “Option”) to acquire a 100% interest (subject to a 2% NSR royalty)…

CURE Pharmaceutical Expands U.S. DEA Approval to Manufacture Pharmaceuticals Using Whole Cannabis Plant

GlobeNewswire•March 12, 2019 OXNARD, Calif., March 12, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has broadened its U.S. Drug Enforcement Administration (DEA) license as an authorized manufacturer of Schedule 1 substances to include both cannabis plant extracts and synthetic cannabidiol (CBD). This license allows CURE…

Energy Fuels Announces 2018 Results

PR Newswire•March 12, 2019 LAKEWOOD, CO, March 12, 2019 /PRNewswire/ – Energy Fuels Inc. (NYSE American: UUUU; TSX: EFR) (“Energy Fuels” or the “Company”), today reported its financial results for the year ended December 31, 2018. The Company’s Annual Report on Form 10-K has been filed with the U.S. Securities and Exchange Commission (“SEC”), and may…

Wealth Closes $1.35m Loan

GlobeNewswire•March 6, 2019 VANCOUVER, British Columbia, March 06, 2019 (GLOBE NEWSWIRE) — Wealth Minerals Ltd. (the “Company” or “Wealth”) – (TSXV: WML; OTCQX: WMLLF; SSE: WMLCL; Frankfurt: EJZN), reports it has closed its loan placement, as announced on February 11, 2019, to third-party lenders as well as an insider. The total loan sum closed is…

Wealth Receives Positive Geophysical Results for the Vapor Lithium Brine Project, Northern Chile and Provides Corporate Update

GlobeNewswire•February 28, 2019 VANCOUVER, British Columbia, Feb. 28, 2019 (GLOBE NEWSWIRE) — Wealth Minerals Ltd. (the “Company” or “Wealth”) – (TSXV: WML; OTCQX: WMLLF; SSE: WMLCL; Frankfurt: EJZN), reports that it has received positive results from geophysical surveys conducted on and around certain concessions in the Company’s Vapor project (the “Vapor Project”), located in the…

Energy Fuels Producing Vanadium at Commercial Levels; Vanadium Shipments Commenced

CNW Group•February 12, 2019 LAKEWOOD, CO , Feb. 12, 2019 /CNW/ – Energy Fuels Inc. (NYSE American: UUUU; TSX: EFR) (“Energy Fuels” or the “Company”), a leading producer of uranium and vanadium in the United States , is pleased to announce that it is now producing high-purity vanadium at commercial rates of approximately 175,000 to 200,000…

National Healthcare Economics and Policy Expert Ruben Jose King-Shaw Jr Joins CURE Pharmaceutical’s Board of Directors

GlobeNewswire• January 29, 2019 The drug delivery leader taps former COO of U.S. Centers for Medicare & Medicaid Services to join growing Board OXNARD, Calif., Jan. 29, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced Ruben Jose King-Shaw Jr. has joined its Board of Directors. King-Shaw brings…

Energy Fuels Commencing Vanadium Production; Testing New Approaches to Mining in Tight Vanadium Market

LAKEWOOD, CO, Sept. 27, 2018 /PRNewswire/ – Energy Fuels Inc. (NYSE American: UUUU; TSX: EFR) (“Energy Fuels” or the “Company”) is pleased to announce that the Company expects to resume vanadium production at its 100% owned White Mesa Mill (the “Mill”) in mid-November 2018, producing significant quantities of salable V2O5 product by the end of…

CURE Pharmaceutical Secures Patent for Oral Thin Film Containing Bioactive Cannabinoid Molecules

CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, announced the allowance of an oral thin film patent (U.S. Patent No. 10092611), which covers the processing and integration of bioactive cannabinoid molecules into oral thin film dosage forms, such as CUREfilm(TM), the most advanced oral thin film on the market today. These molecules such…